



Moxifloxacin 400 mg Injectable

The Issue: Moxifloxacin 400 mg ready-to-use (RTU) injectable bags are on full backorder from the sole source vendor and all NH supply will expire on October 31, 2021. This is a relatively low use item in NH, but there will be a supply gap of approximately 3 months after our existing stock expires.

Anticipated Availability: end of January 2022

Clinical Use: broad-spectrum antibiotic (respiratory fluoroquinolone)

Practice Implications:

- Clinicians should be aware of this shortage and potential alternatives.
- Remaining supply of moxifloxacin injectable should be reserved for use when absolutely necessary (i.e. empiric treatment for severe community acquired pneumonia in combination with ceftriaxone when macrolide is not appropriate).
- Oral moxifloxacin should be used whenever clinically appropriate as it has very high oral bioavailability.
 - See *Antimicrobial IV to PO Conversion* listed under *Treatment Guidelines* in the NH version of the [Firstline \(formerly Spectrum\)](#) app.
- Levofloxacin remains available as an alternative injectable respiratory fluoroquinolone.
- Clinicians can review NH-specific antimicrobial treatment guidelines on the Firstline app and/or discuss therapeutic alternatives with their local pharmacist(s).

Potential Alternatives*:

- Moxifloxacin 400 mg oral tablets
- Levofloxacin 5 mg/mL X 100 mL and 150 mL RTU injectable bags

October 8, 2021 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage	✓	For further information contact: Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		

*Alternatives are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.